Illumina, Inc. — 6.95/10
Illumina is the dominant next-generation-sequencing (NGS) platform — the picks-and-shovels layer of genomics. It sells sequencers and, more importantly, the proprietary consumables (flow cells, reagents) that run on them in a razor/razor-blade model where instruments seed a locked-in recurring consumables stream (~66% of revenue). Post-GRAIL spin (2024), this is a pure-play "Core Illumina" franchise with >90% of clinical genomics testing and ~66–80% of the global NGS installed base.
The core story: ILMN is a textbook worse-to-better inflection. After two years of declining revenue (GRAIL spin, China collapse, NIH overhang), top-line YoY turned positive in 2H25 and is accelerating (+0.4% → +5.0% → +4.8%), FCF YoY just flipped positive (+20.7% in Q1'26), annual FCF margin tripled (7%→21%), and the share count is flat-to-declining with a new $1.5B buyback. The single thing holding the composite below 7.5 is the risk dimension (4/10) — a premium-to-peers multiple plus two exogenous regulatory overhangs (a proposed ~40% NIH budget cut and China's Unreliable Entities List).
| CEO | Jacob Thaysen (~2.75 yrs) | Revenue Growth | Inflecting (+4.8% Q1'26) |
| Secular Theme | DNA sequencing (NGS) | FCF Trajectory | Growing ($337M→$931M) |
| GRAIL | Spun off (2024) | FYE | December 31 |
| Quality Gate | PASS (0 NOs) | Margin Trend | Op margin expanding |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 7 | 25% | 1.75 |
| Thematic Exposure | 8 | 35% | 2.80 |
| Management Quality | 7 | 20% | 1.40 |
| Investor Sentiment (Inverted) | 8 | 5% | 0.40 |
| Concerns / Risks | 4 | 15% | 0.60 |
| Composite | 100% | 6.95 |
A high-quality, dominant picks-and-shovels genomics franchise in a worse-to-better fundamental inflection. Revenue YoY has re-accelerated for three straight quarters (+0.4% / +5.0% / +4.8%), FCF just flipped positive (+20.7% YoY in Q1'26), FCF margin has tripled (7%→21%), and the share count is flat-to-declining with a new $1.5B buyback. Scores 6.95/10 on the strength of a near-monopoly theme (8/10), an inflecting financial profile (7/10), a strong management track record (7/10), and a genuine management-vs-street divergence (8/10) — dragged down by the risk dimension (4/10).
Quality gate: PASS (0 NOs). Oligopoly YES (>90% clinical NGS share, near-monopoly). Positive & growing FCF YES ($337M→$931M, 2021-2025). Management track record YES (~100% scoreable promise hit-rate). No composite cap applied.
Illumina is the reference NGS platform: >90% of clinical genomics testing runs on its chemistry, and ~66–80% of the global installed base is Illumina. The moat is a razor/razor-blade consumables annuity (~66% of revenue) protected by multi-year switching costs — clinical customers run FDA-cleared assays locked to Illumina chemistry, and revalidating a regulated assay on a rival platform takes years. Management is a clear price-maker, running an "elasticity game" on price-per-gigabase to drive volume on its own terms.
The financial inflection is real and young: after two years of decline (GRAIL spin, China collapse, NIH overhang), the exit rate (+5% / +4.8%) and the FY26 guide (+4–6%) confirm reacceleration, while FCF margin has tripled off the 2022 trough. The one genuine tension is the management-vs-street divergence: management is loudly bullish on NovaSeq X demand and clinical durability while the street stays at Hold and treats the beats as one-offs.
The binding constraint is the risk dimension. The stock has re-rated to a premium versus large-cap tools peers while carrying two exogenous overhangs — a proposed ~40% NIH cut (with ~44% of the customer base academic/government) and China's Unreliable Entities List. Quality and theme are not in question; the margin of safety and the funding/geopolitical tail are.